Nanobiotix S.A. Logo

Nanobiotix S.A.

Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.

NBTX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
60 RUE DE WATTIGNIES, 75012 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering the discovery, development, and commercialization of physics-based nanotherapeutics. The company's lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed for direct injection into solid tumors. When activated by radiotherapy, NBTXR3 locally amplifies the radiation dose within the tumor, aiming to enhance cancer cell destruction without increasing exposure to surrounding healthy tissues. This process is also intended to prime the immune system to attack metastatic cancer cells. Through a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, Nanobiotix is co-developing NBTXR3, initially focusing on cancers of the head, neck, and lungs for patient populations with limited treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Nanobiotix S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland
NANOFH
NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland
NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany
NN6
NANOVIRICIDES, INC. Logo
Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.
United States of America
NNVC
Nasus Pharma Ltd Logo
Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.
United States of America
NSRX
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain
NAT
Natera, Inc. Logo
Provides non-invasive cfDNA tests for oncology, women's health, and organ health.
United States of America
NTRA
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea
168330

Talk to a Data Expert

Have a question? We'll get back to you promptly.